S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Closing prices for crude oil, gold and other commodities
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
New highs are coming for Lowe’s stock despite mixed results
Nvidia and S&P 500 rallies: Cracks in the armor?

Relay Therapeutics (RLAY) Competitors

$10.29
+0.13 (+1.28%)
(As of 02/27/2024 ET)

RLAY vs. VIR, BCRX, FDMT, ADMA, AUTL, SANA, SRRK, TARS, APGE, and AMAM

Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Vir Biotechnology (VIR), BioCryst Pharmaceuticals (BCRX), 4D Molecular Therapeutics (FDMT), ADMA Biologics (ADMA), Autolus Therapeutics (AUTL), Sana Biotechnology (SANA), Scholar Rock (SRRK), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), and Ambrx Biopharma (AMAM). These companies are all part of the "biological products, except diagnostic" industry.

Relay Therapeutics vs.

Relay Therapeutics (NASDAQ:RLAY) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

In the previous week, Vir Biotechnology had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 31 mentions for Vir Biotechnology and 19 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.66 beat Vir Biotechnology's score of 0.15 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relay Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Vir Biotechnology
5 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Relay Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.

Relay Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Relay Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay Therapeutics$25.55M52.83-$341.97M-$2.80-3.68
Vir Biotechnology$86.18M17.84-$615.06M-$4.59-2.49

67.1% of Vir Biotechnology shares are held by institutional investors. 3.5% of Relay Therapeutics shares are held by insiders. Comparatively, 18.1% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Relay Therapeutics and Vir Biotechnology both received 36 outperform votes by MarketBeat users. However, 59.02% of users gave Relay Therapeutics an outperform vote while only 46.75% of users gave Vir Biotechnology an outperform vote.

CompanyUnderperformOutperform
Relay TherapeuticsOutperform Votes
36
59.02%
Underperform Votes
25
40.98%
Vir BiotechnologyOutperform Votes
36
46.75%
Underperform Votes
41
53.25%

Relay Therapeutics currently has a consensus target price of $24.17, indicating a potential upside of 134.86%. Vir Biotechnology has a consensus target price of $34.38, indicating a potential upside of 200.74%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Relay Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relay Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Vir Biotechnology
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Vir Biotechnology has a net margin of -713.69% compared to Relay Therapeutics' net margin of -1,263.49%. Vir Biotechnology's return on equity of -34.92% beat Relay Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relay Therapeutics-1,263.49% -42.43% -36.47%
Vir Biotechnology -713.69%-34.92%-27.73%

Summary

Relay Therapeutics and Vir Biotechnology tied by winning 9 of the 18 factors compared between the two stocks.


Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLAY vs. The Competition

MetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.33B$2.84B$5.01B$7.50B
Dividend YieldN/A2.33%2.90%3.88%
P/E Ratio-3.6823.48201.1315.35
Price / Sales52.83241.663,143.9765.20
Price / CashN/A29.7788.0252.50
Price / Book1.804.374.444.69
Net Income-$341.97M-$4.61M$112.02M$210.92M
7 Day Performance-1.81%6.99%5.27%2.96%
1 Month Performance5.86%16.10%13.32%5.38%
1 Year Performance-36.28%12.07%13.30%8.21%

Relay Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIR
Vir Biotechnology
3.0385 of 5 stars
$10.23
-0.2%
$34.25
+234.8%
-50.5%$1.38B$1.62B-2.28576Earnings Report
Insider Selling
BCRX
BioCryst Pharmaceuticals
3.9112 of 5 stars
$5.82
-1.7%
$13.63
+134.1%
-35.0%$1.19B$270.83M-4.66531News Coverage
FDMT
4D Molecular Therapeutics
1.514 of 5 stars
$27.39
+0.5%
$39.44
+44.0%
+54.4%$1.17B$3.13M-10.03144Gap Up
ADMA
ADMA Biologics
2.5012 of 5 stars
$5.15
-2.5%
$6.75
+31.1%
+58.2%$1.16B$154.08M-46.82617Positive News
AUTL
Autolus Therapeutics
2.9816 of 5 stars
$6.66
-2.5%
$7.97
+19.7%
+218.1%$1.16B$6.36M-6.80399Upcoming Earnings
SANA
Sana Biotechnology
0.8522 of 5 stars
$8.14
-6.2%
$9.75
+19.8%
+168.6%$1.60BN/A-5.65418
SRRK
Scholar Rock
4.1094 of 5 stars
$15.01
-5.4%
$24.75
+64.9%
+100.5%$1.08B$33.19M-7.70114Upcoming Earnings
Gap Up
TARS
Tarsus Pharmaceuticals
1.3402 of 5 stars
$30.42
-0.9%
$43.20
+42.0%
+161.6%$1.01B$25.82M-7.9687Analyst Revision
News Coverage
Gap Up
APGE
Apogee Therapeutics
0.5363 of 5 stars
$34.50
-4.0%
$38.33
+11.1%
N/A$1.75BN/A0.0025Upcoming Earnings
Positive News
AMAM
Ambrx Biopharma
0.3196 of 5 stars
$27.74
-0.1%
$24.13
-13.0%
+399.3%$1.75B$7.40M0.0087

Related Companies and Tools

This page (NASDAQ:RLAY) was last updated on 2/28/2024 by MarketBeat.com Staff